Browse by Poster Author

iwCLL X / Twitter

Browse by Poster Author

Type here to filter the list

T
T. Pezacki, Aidan

University of California
1006 - ApoliproteinE induces ferroptosis in chronic lymphocytic leukaemia cells
Aidan T. Pezacki
Favorite
Tabang, Dylan

Boston Children's Hospital, Harvard Medical School
1001 - IgM Monoclonal Gammopathy Arises Directly from MBL/CLL Cells: Evidence from Proteomic Analyses
Dylan Tabang
Favorite
Tadmor, Tamar

Bnai Zion Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine
1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL
Tamar Tadmor
Favorite
1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial
Tamar Tadmor
Favorite
1511 - Nemtabrutinib in Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Phase 3 BELLWAVE-011 Study
Tamar Tadmor
Favorite
Tafuri, Agostino

Tafuri Ematologia, AOU Sant'Andrea, Sapienza Università di Roma
1709 - Impact of Dose Intensity of Ibrutinib on Clinical Outcomes of CLL Patients: Analysis of the EVIdeNCE Study
Agostino Tafuri
Favorite
Takvorian, Ronald

Center for Lymphoma, Massachusetts General Hospital Cancer Center
1517 - Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis
Ronald Takvorian
Favorite
Talbot, Georgina

University Hospitals of North Midlands
1711 - A 3 week pause versus continued BTKi during vaccination (IMPROVE): a randomised, open-label, superiority trial.
Georgina Talbot
Favorite
Tam, Constantine S.

Alfred Hospital and Monash University
1414 - Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia /small lymphocytic lymphoma in the phase 2 CAPTIVATE study
Constantine S. Tam
Favorite
1419 - SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Constantine S. Tam
Favorite
1420 - Combination of Zanubrutinib + Venetoclax for Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D
Constantine S. Tam
Favorite
1421 - Safety and Efficacy of Zanubrutinib in a Subgroup of Older Patients (≥75 Years) With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the SEQUOIA Study
Constantine S. Tam
Favorite
1426 - Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Post Hoc Analyses from the SEQUOIA Study
Constantine S. Tam
Favorite
1514 - Updated Results From the Phase 1 Study of Sonrotoclax (BGB-11417), a Novel B-Cell Lymphoma 2 Inhibitor, in Combination With Zanubrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Demonstrate Deep and Durable Responses
Constantine S. Tam
Favorite
1524 - Patient-Reported Outcomes (PRO) among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) receiving Pirtobrutinib: Final Analysis from the BRUIN Phase 1/2 Study
Constantine S. Tam
Favorite
1525 - Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study
Constantine S. Tam
Favorite
Tan, Amandine

Department of Haematology, Comprehensive Cancer Centre, King’s College London
1224 - A fraction of lymph node CLL B cells exhibits high expression of T-bet
Amandine Tan
Favorite
Tancredi, Gaspare

University of Pisa
1513 - Comparative Assessment of MRD Detection and Immunological Effects in Relapsed CLL Patients Treated with Rituximab-Venetoclax in real world: Insights from the "Dedalus" Protocol
Gaspare Tancredi
Favorite
Tan, Fenlai

Newave Pharmaceutical Inc.
1801 - Targeting BTKi-Resistant CLL Using the Dual Irreversible/Reversible 4th Generation BTK Inhibitor Rocbrutinib
Fenlai Tan
Favorite
Tang, Hanning

the First Affiliated Hospital with Nanjing Medical University
1429 - Orelabrutinib, fludarabine, cyclophosphamide and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter, investigator-initiated phase II trial (cwcll-001 trial)
Hanning Tang
Favorite
Tan, He

Department of Haematology, Comprehensive Cancer Centre, King’s College London
1224 - A fraction of lymph node CLL B cells exhibits high expression of T-bet
He Tan
Favorite
Tani, Monica

Santa Maria delle Croci Hospital
1420 - Combination of Zanubrutinib + Venetoclax for Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D
Monica Tani
Favorite
1709 - Impact of Dose Intensity of Ibrutinib on Clinical Outcomes of CLL Patients: Analysis of the EVIdeNCE Study
Monica Tani
Favorite
Tan, May

Nurix Therapeutics, Inc.
1312 - Zelebrudomide (NX-2127) is a cereblon-modulating BTK degrader that reverses immune dysfunction and modifies both T-cell and CLL-cell transcriptional signatures in patients with CLL
May Tan
Favorite
Tantoush, Fisal

Brighton and Sussex Medical School
1226 - Ibrutinib enhances the bias of T-cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia
Fisal Tantoush
Favorite
Tapken, Claas

Department of Internal Medicine I, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany
1221 - The Integrin Adaptor Kindlin-3 Regulates Chronic Lymphocytic Leukemia Development and Progression
Claas Tapken
Favorite
Tapprich, Christoph

Johnson & Johnson
1409 - Factors influencing physician’s choice of fixed-duration ibrutinib+venetoclax or continuous ibrutinib monotherapy in the treatment of patients with previously untreated CLL: physician questionnaire results from the prospective phase 2 TAILOR study
Christoph Tapprich
Favorite
Tascini, Anna Sofia

Center for Omics Sciences, San Raffaele Hospital (IRCCS)
1016 - Integrating phosphoproteomic analysis and innovative 3D cell culture systems to dissect the role of extracellular stiffness in CLL pathogenesis
Anna Sofia Tascini
Favorite
Tasso, Bruno

Department of Pharmacy, University of Genoa, Genoa, Italy
1805 - Targeting the p53/xCT/GSH axis with PRIMA-1Met combined with Sulfasalazine shows therapeutic potential in Chronic Lymphocytic Leukemia
Bruno Tasso
Favorite
Tatara, Katarzyna

Lower Silesian Center for Oncology, Pulmonology and Hematology in Wroclaw, Wroclaw, Poland
LB07 - Risk Stratification in Chronic Lymphocytic Leukemia by IgHV Status and Mutational Co-Occurrence Profiling
Katarzyna Tatara
Favorite
Taušová, Kristýna

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Central European Institute of Technology, Masaryk University, Brno, Czech Republic
1007 - Clonality assessment in multiclonal chronic lymphocytic leukemia using Sanger and next-generation sequencing approaches
Kristýna Taušová
Favorite
1114 - Clonal shifts of TP53 mutations in patients treated with BTK and BCL2 inhibitors: analysis of accompanying genomic changes
Kristýna Taušová
Favorite
Tausch, Eugen

Division of CLL, Department of Internal Medicine III, University Hospital Ulm
1104 - A Multi-Gene Expression-Based Prognostic Model for Risk Stratification in Chronic Lymphocytic Leukemia (CLL)
Eugen Tausch
Favorite
1108 - CLL10000: Robust Classification of 1172 ATM Variants employing a Five-Factor Score derived from matched Non-Tumor Controls
Eugen Tausch
Favorite
1111 - Functional analysis of in-frame variants in TP53 gene identified in adult leukemias: A study of the TP53 Network of European Research Initiative on CLL
Eugen Tausch
Favorite
1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL
Eugen Tausch
Favorite
1418 - A Refined Continuous Individualized Risk Index (CIRI2-CLL) for Accurately Predicting Outcomes after Limited-Duration CLL Therapy
Eugen Tausch
Favorite
1425 - IGLV3-21R110 as a prognostic marker for early stage CLL patients – clinical implications in patients treated with BTK inhibitors and diagnostic challenges
Eugen Tausch
Favorite
1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial
Eugen Tausch
Favorite
1515 - Re-Treatment with Venetoclax-Obinutuzumab after time-limited, MRD-guided Venetoclax-Obinutuzumab: final analysis of 7 patients with chronic lymphatic leukemia (CLL) treated in the CLL2-BAG trial of the GCLLSG.
Eugen Tausch
Favorite
Tchernonog, Emmanuelle

CHU Montpellier
1704 - Feasibility of an individualized physical activity Intervention in CLL patients receiving ibrutinib +/-venetoclax: preliminary results from the QOLIBRI Study
Emmanuelle Tchernonog
Favorite
Tedeschi, Alessandra

ASST Grande Ospedale Metropolitano Niguarda
1402 - Cytogenetic instability and therapeutic pressure in Fixed vs Continuous regimens for Chronic Lymphocytic Leukemia after first line treatment: Preliminary Data from an Italian Multicenter Experience
Alessandra Tedeschi
Favorite
1414 - Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia /small lymphocytic lymphoma in the phase 2 CAPTIVATE study
Alessandra Tedeschi
Favorite
1420 - Combination of Zanubrutinib + Venetoclax for Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D
Alessandra Tedeschi
Favorite
1421 - Safety and Efficacy of Zanubrutinib in a Subgroup of Older Patients (≥75 Years) With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the SEQUOIA Study
Alessandra Tedeschi
Favorite
1424 - Safety Analysis of Fixed-Duration Acalabrutinib-Venetoclax Combinations vs Chemoimmunotherapy: A Post Hoc Analysis From the Phase 3 AMPLIFY Trial
Alessandra Tedeschi
Favorite
1514 - Updated Results From the Phase 1 Study of Sonrotoclax (BGB-11417), a Novel B-Cell Lymphoma 2 Inhibitor, in Combination With Zanubrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Demonstrate Deep and Durable Responses
Alessandra Tedeschi
Favorite
1708 - Chronic Obstructive Pulmonary Disease and Previous Pneumonia have an impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with Acalabrutinib and Zanubrutinib: a Multicentre SEIFEM Study.
Alessandra Tedeschi
Favorite
1709 - Impact of Dose Intensity of Ibrutinib on Clinical Outcomes of CLL Patients: Analysis of the EVIdeNCE Study
Alessandra Tedeschi
Favorite
Teferi, Yegnasew

Department of Haematology, Comprehensive Cancer Centre, King’s College London
1224 - A fraction of lymph node CLL B cells exhibits high expression of T-bet
Yegnasew Teferi
Favorite
Teo, James

King's College Hospital NHS Foundation Trust
1701 - Development and evaluation of a selection-algorithm optimised ensemble model for predicting infection risk in CLL using structured and unstructured electronic patient record data
James Teo
Favorite
Terol, María José

Hematology Service, Valencia University Clinical Hospital, Valencia 46010, Spain. INCLIVA Biomedical Research Institute, Valencia 46010, Spain.Medicine Department, University of Valencia, Valencia 46010, Spain.
1115 - Clonal Evolutionary Dynamics Shaped by Genetic Profiles in Chronic Lymphocytic Leukemia: A New Era in Disease Monitoring and Therapy Resistance
María José Terol
Favorite
1116 - IGHV Next-Generation Sequencing in CLL: Integrating Mutational Status and Clonotype Tracking for MRD Assessment
María José Terol
Favorite
Terzi Di Bergamo, Lodovico

Laboratory of Experimental Hematology, Institute of Oncology Research
1107 - Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation
Lodovico Terzi Di Bergamo
Favorite
1122 - Integrative epi(genome) analysis of CD49d bimodal expression reveals epigenetically driven phenotypic transitions in CLL
Lodovico Terzi Di Bergamo
Favorite
Texier, Nathalie

Kappa Santé
1704 - Feasibility of an individualized physical activity Intervention in CLL patients receiving ibrutinib +/-venetoclax: preliminary results from the QOLIBRI Study
Nathalie Texier
Favorite
Thangavadivel, Shanmugapriya

The Ohio State University
1801 - Targeting BTKi-Resistant CLL Using the Dual Irreversible/Reversible 4th Generation BTK Inhibitor Rocbrutinib
Shanmugapriya Thangavadivel
Favorite
Thomas, Kersten

Department of Nursing, Mayo Clinic
1502 - Sequencing single novel agent-based therapy for patients with CLL: A retrospective study of patients treated with covalent Bruton Tyrosine Kinase inhibitor (cBTKi) followed by B-cell lymphoma 2 inhibitor (BCL2i) versus BCL2i followed by cBTKi
Kersten Thomas
Favorite
Thomas, Sandra

City of Hope
1717 - MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia (CLL) compared with mRNA-based vaccine: initial results of a Phase II randomized study
Sandra Thomas
Favorite
Thompson, Meghan

Memorial Sloan Kettering Cancer Center
1525 - Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study
Meghan Thompson
Favorite
1606 - Epcoritamab Monotherapy in Patients with First-Line Richter’s Transformation: 2-Year Follow-Up Results From the Phase 1b/2 EPCORE CLL-1 Clinical Trial
Meghan Thompson
Favorite
1803 - Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study
Meghan Thompson
Favorite
Thornton, Patrick

Cancer Clinical Trials Unit, Beaumont Hospital
1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL
Patrick Thornton
Favorite
1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial
Patrick Thornton
Favorite
Thurgood, Lauren

Flinders University
1307 - Developing a novel lipid-based imaging tool for the surveillance of chronic lymphocytic leukemia
Lauren Thurgood
Favorite
1806 - Dual mTORC1/2 Inhibition by Torin 2 Induces Cytotoxic and Cytostatic Effects in In Vitro Models of Chronic Lymphocytic Leukaemia
Lauren Thurgood
Favorite
Tian, Tian

BeOne Medicines Ltd
1419 - SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Tian Tian
Favorite
1420 - Combination of Zanubrutinib + Venetoclax for Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D
Tian Tian
Favorite
1421 - Safety and Efficacy of Zanubrutinib in a Subgroup of Older Patients (≥75 Years) With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the SEQUOIA Study
Tian Tian
Favorite
1426 - Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Post Hoc Analyses from the SEQUOIA Study
Tian Tian
Favorite
Tickler, Georgina

Acaster Lloyd Consulting Ltd
1706 - A Qualitative Study to Explore the Patient Experience of Continuous Covalent Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Study Methodology
Georgina Tickler
Favorite
Tiemann, Katrin

City of Hope
1717 - MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia (CLL) compared with mRNA-based vaccine: initial results of a Phase II randomized study
Katrin Tiemann
Favorite
Tissino, Erika

Centro di Riferimento Oncologico di Aviano
1122 - Integrative epi(genome) analysis of CD49d bimodal expression reveals epigenetically driven phenotypic transitions in CLL
Erika Tissino
Favorite
Tizro, Parastou

City of Hope
1904 - Development and implementation of a novel flow cytometry CD19-agnostic MRD assay in CLL, including in patients treated with anti-CD19 antibody tafasitamab
Parastou Tizro
Favorite
Tomasso, Annamaria

Section of Hematology, Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Rome, Italy
1220 - Chronic Lymphocytic Leukemia and Renal Cell Carcinoma: A Case Series of Twelve Patients
Annamaria Tomasso
Favorite
1435 - Absence of lymphocytosis after starting treatment with cBTKi is a rare phenomenon except for trisomy 12 and CD49d positive CLL
Annamaria Tomasso
Favorite
Tomowiak, Cecile

Service Hématologie, CHU Poitiers
1413 - A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 ICLL-07 FILO trial
Cecile Tomowiak
Favorite
Totev, Todor

Analysis Group
1911 - Prospective Patient Preference Study for Chronic Lymphocytic Leukemia (CLL) Treatment Attributes Impacting Patient Shared-Decision Making
Todor Totev
Favorite
Tournilhac, Olivier

CHU Estaing, Clermont-Ferrand University Hospital
1413 - A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 ICLL-07 FILO trial
Olivier Tournilhac
Favorite
1507 - Allogeneic stem cell transplantation is effective after pathway inhibitor treatments in CLL – a retrospective study on behalf of the Chronic Malignancies Working Party of EBMT
Olivier Tournilhac
Favorite
Tran, Hoa TT

Akershus University Hospital
1441 - A functional prognostic model predicts progression free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax
Hoa TT Tran
Favorite
Traverso, Nicola

Department of Experimental Medicine, University of Genoa, Genoa, Italy
1805 - Targeting the p53/xCT/GSH axis with PRIMA-1Met combined with Sulfasalazine shows therapeutic potential in Chronic Lymphocytic Leukemia
Nicola Traverso
Favorite
Trentin, Livio

Hematology Unit, University of Padova
1022 - Unravelling the Clinical and Biological Features of Accelerated Chronic Lymphocytic Leukemia
Livio Trentin
Favorite
1107 - Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation
Livio Trentin
Favorite
1402 - Cytogenetic instability and therapeutic pressure in Fixed vs Continuous regimens for Chronic Lymphocytic Leukemia after first line treatment: Preliminary Data from an Italian Multicenter Experience
Livio Trentin
Favorite
1414 - Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia /small lymphocytic lymphoma in the phase 2 CAPTIVATE study
Livio Trentin
Favorite
1708 - Chronic Obstructive Pulmonary Disease and Previous Pneumonia have an impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with Acalabrutinib and Zanubrutinib: a Multicentre SEIFEM Study.
Livio Trentin
Favorite
1709 - Impact of Dose Intensity of Ibrutinib on Clinical Outcomes of CLL Patients: Analysis of the EVIdeNCE Study
Livio Trentin
Favorite
Trigo-Miranda, Mariana

Serviço de Hematologia Clínica, ULS Viseu Dão-Lafões
1520 - Unveiling the journey of Chronic Lymphocytic Leukemia patients in Portugal: insights into the Rituximab-Venetoclax protocol
Mariana Trigo-Miranda
Favorite
Trotman, Judith

Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia
1525 - Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study
Judith Trotman
Favorite
Troussard, Xavier

Caen University Hospital
1521 - Real-world efficacy and safety of venetoclax +/- rituximab in >75-years old patients or with cardiovascular comorbidities and R/R chronic lymphocytic leukemia: interim results of the VERONE study
Xavier Troussard
Favorite
Truchan, Margot

CH saumur
1413 - A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 ICLL-07 FILO trial
Margot Truchan
Favorite
Tryc-Szponder, Jagoda

Poznan University of Medical Sciences, Department of Hematology and Bone Marrow Transplantation
1501 - EFFICACY AND TOLERABILITY OF VENETOCLAX PLUS RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA – REAL-WORLD ANALYSIS OF POLISH ADULT LEUKEMIA STUDY GROUP
Jagoda Tryc-Szponder
Favorite
Tsang, Mazie

Department of Hematology, Mayo Clinic
1502 - Sequencing single novel agent-based therapy for patients with CLL: A retrospective study of patients treated with covalent Bruton Tyrosine Kinase inhibitor (cBTKi) followed by B-cell lymphoma 2 inhibitor (BCL2i) versus BCL2i followed by cBTKi
Mazie Tsang
Favorite
1601 - Central Nervous System Involvement in Patients with Richter Transformation
Mazie Tsang
Favorite
Tsertsvadze, Tamar

Ivane Javakhishvili Tbilisi State University
1215 - Expression and signalling patterns of CD180/MD1 and CD150 in Chronic Lymphocytic Leukaemia (CLL) cells and MEC 1 cell line
Tamar Tsertsvadze
Favorite
Tsuji, Junko

Cancer Program, Broad Institute of MIT and Harvard
1219 - The immunogenicity landscape of CLL and its association with patient outcome
Junko Tsuji
Favorite
Tsuriel, Shlomo

Clinical Pathology Laboratory, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
1217 - IGHV Repertoire in Israeli CLL Patients Reveals Significant Low Frequency of Stereotyped Subsets – A Single Center Retrospective Study
Shlomo Tsuriel
Favorite
Tudur Smith, Catrin

University of Liverpool, Liverpool, UK
1705 - Inequalities in the diagnosis and survival of 30,071 people consecutively diagnosed with chronic lymphocytic leukaemia in England between 2014 and 2021: preliminary analysis from the UNCOVER Study Group
Catrin Tudur Smith
Favorite
Tuffnell, Joe

EBMT Leiden Study Unit
1507 - Allogeneic stem cell transplantation is effective after pathway inhibitor treatments in CLL – a retrospective study on behalf of the Chronic Malignancies Working Party of EBMT
Joe Tuffnell
Favorite
Tuncer, Hande

Dana-Farber Cancer Institute
1803 - Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study
Hande Tuncer
Favorite
Tun, Han

Department of Hematology, Mayo Clinic
1601 - Central Nervous System Involvement in Patients with Richter Transformation
Han Tun
Favorite
Turcsanyi, Peter

Department of Hemato-oncology, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc
1516 - Real-World Outcomes of Idelalisib in Relapsed/Refractory CLL Including High-Risk Patients and Post-BTKi/BCL2 Therapy: A Single-Center Experience from 2016 to 2025
Peter Turcsanyi
Favorite
Turner, James

University of Birmingham
1003 - A Phenotypically Distinct Population of CLL Cells with Lower CD20 Expression is Present Within Abdominal Subcutaneous Adipose Tissue of Patients with CLL
James Turner
Favorite